UrokinaseType Plasminogen Activator Receptor Expression In Colorectal Neoplasms

Authors

  • Rasha Qusai AL-Jawher

Abstract

BackgroundThe urokinase type plasminogen activator receptor (uPAR) may play a critical role in cancer invasion and metastasis. AimsTo study the involvement of uPAR in colorectal carcinogenesis. Methodsfourty four cases of colorectal adenocarcinoma were obtained and diagnosed as colonic carcinoma with it's grade received as formalin fixed, paraffin embedded tissue in AL-nassiriyah teaching hospital with cases of carcinoma also 6 cases of normal endoscopic biopsies used as control –ve and 10 cases of adenoma with dysplastic changes all these cases stain by immunohistochemical methods for expression and localisation of uPAR. Results_all the cases of endoscopic biopsies were –ve for this receptors so used as –ve control, while cases of adenoma 3 out of 10 cases showing focal positivity in areas of dysplasia, while the cases of invasive carcinoma showing diffused positivity and the case percent of positivity depend on grade so high grade tumor showing high percentage of positivity. ConclusionsColorectal adenoma uPAR, expressed essentially in dysplastic epithelial cells, was upregulated with increasing severity of atypia, and increased notably during the critical transition from severe dysplasic adenoma to invasive carcinoma. These findings implicate uPAR expression in the invasive and metastatic processes of colorectal cancer.

References

-Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics.

CA Cancer J Clin 2005, 55:10-30. PubMed Abstract | Publisher Full Text

- Greenwald P: Colon cancer overview.

Cancer 1992, 70:1206-1215. PubMed Abstract | Publisher Full Text

- 15. Fearon,E.R. and Vogelstein,B. (1990) A genetic model for colorectal

tumorigenesis. Cell, 61, 759–767.

Kohonen-Corish,M., Ross,V.L., Doe,W.F. et al. (1996) RNA-based

mutation screening in hereditary nonpolyposis colorectal cancer. Am. J.

Human Genet., 59, 818–824.

-MutoT,BusseyHJR, MorsonBC

(1975) The evolution of cancer of the colon and rectum. Cancer 36:2251–2270.

- Dahiya R, Yoon W, Boyle B, Schoenberg S, Yen T, Narayan P: Biochemical, cytogenetic, and morphological characteristics of human primary and metastatic prostate cancer cell lines.

BiochemInt 1992, 27:567-577. PubMed Abstract

- Mook ORF, Frederiks WM, Van Noorden CJF: The role of gelatinases in colorectal cancer progression and metastasis.

BiochimBiophysActa 2004, 1705:69-89. PubMed Abstract | Publisher Full Text

-Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

Eur J Cell Biol 1997, 74:111-122. PubMed Abstract

- Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review.

Int J Cancer 1997, 72:1-22. PubMed Abstract | Publisher Full Text

- Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK: Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol 2005, 28:3046-3050.

- Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review.

Int J Cancer 1997, 72:1-22. PubMed Abstract | Publisher Full Text

- Seetoo DQ, Crowe PJ, Russell PJ, Yang JL: Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.

J SurgOncol 2003, 82:184-193. PubMed Abstract | Publisher Full Text

-Harvey SR, Sait SNJ, Xu Y, Bailey JL, Penetrante RM, Markus G: Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.

Am J Pathol 1999, 155:1115-1120. PubMed Abstract | Publisher Full Text

-TryggvasonK,HöyhtyäM, SaloT

(1987) Proteolytic degradation of extracellular matrix in tumor invasion.BiochemBiophysActa907:191–217.

-NielsenBS, SehestedM, TimshelS, et al.

(1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74:168–177.

-GaneshS, SierCFM, HeerdingMM, et al.

(1994) Urokinase receptor and colorectal cancer survival. Lancet 344:401–402.

-WangH, SkibberJ, JuarezJ, et al

(1994) Transcriptional activation of the urokinase receptor gene in invasive colon cancer.Int J Cancer 58:650–657.

-MinHY, DoyleLV, VittCR, et al.

(1996) Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56:2428–2433.

-GelisterJSK, LewinMR, SavageF, et al.

(1987) Plasminogen activators in experimental colorectal neoplasia: a role in adenoma-carcinoma sequence? Gut 28:816–821.

-SuzumiyaJ,HasuiY,KohgaS, et al.

Downloads

Published

2020-02-26

Issue

Section

Articles